

The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: a case series and literature review

Paola Zagami¹, Eleni Kandaraki², Giuseppe Renne², Franco Grimaldi³, Francesca Spada¹, Alice Laffi¹ and Nicola Fazio¹

¹Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours, European Institute of Oncology, IEO, IRCCS, Milan 20132, Italy

²Department of Pathology, European Institute of Oncology, Milan 20132, Italy

³Endocrinology and Metabolism Unit, University of Udine, Italy

Abstract

Introduction: Primary neuroendocrine neoplasms (NENs) in the breast are very rare. Until 2011, the prevalence was 0.1% of all breast lesions and 1% of all NENs, whereas metastatic breast NENs represent 1%–2% of all breast tumours. However, it seems that over the last 5 years the diagnostic frequency of breast NENs has increased, probably for more alert specialists and advanced diagnostic tools, leading to a prevalence of 2%–5% of diagnosed breast cancers, mostly in the elderly population. Breast metastases from extramammary malignancies are uncommon and bilateral ones are even more uncommon, with few reported in the literature. We describe four clinical settings of breast metastases from different NENs and the multidisciplinary approach for diagnosis and treatment.

Methods: Four patients were found to have NEN primaries metastasised to the breast. A literature review was conducted to identify similar cases and characterise breast metastases from neuroendocrinal tumors (NETs).

Results: Two patients presented with bilateral breast metastases (one with well-differentiated panNET and another with atypical lung carcinoid) and two had unilateral (one with moderately differentiated lung NET and one with atypical lung carcinoid). There are about 13 cases of NEN breast metastases reported in the English literature. The ileum is the most common primary site, followed by the appendix, duodenum, pancreas and lung.

Conclusion: Breast lesions from extramammary primary often pose a diagnostic challenge, since a breast nodule can be the first and often the only presentation of the disease. However, differentiating between primary and secondary NEN breast lesions is essential, owing to different clinical management and prognosis.

Keywords: *bilateral, breast metastases, neuroendocrine, neuroendocrine neoplasms, neuroendocrine tumours*

Introduction

Breast metastases from extramammary malignancies are uncommon, representing approximately 2% of breast masses [1, 2]. The contralateral breast, haematological malignancies, melanomas, carcinomas and sarcomas are the primary sites for the majority of

Correspondence to: Paola Zagami
Email: paola.zagami@ieo.it

ecancer 2020, 14:1123
<https://doi.org/10.3332/ecancer.2020.1123>

Published: 15/10/2020

Received: 03/05/2020

Publication costs for this article were supported by ecancer (UK Charity number 1176307).

Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

breast metastases [3–6]. Most cases have been reported in female patients, while male breast metastases seem to be very infrequent [7–10]. Bilateral metastases to the breast are even more uncommon, with only very few reported in the literature [11]. Primary neuroendocrine neoplasms (NENs) in the breast are very rare. Up until 2011, the prevalence was less than 0.1% of all breast lesions and less than 1% of all NENs, whereas metastatic NENs lesions involving the breast represent only 1%–2% of all breast tumours [1]. However, it seems that over the last 5 years the diagnostic frequency of primary breast NENs has increased, leading to an estimated prevalence of 2%–5% of diagnosed breast cancers, affecting mostly the elderly population aged between 60 and 80 years [12–16]. The first case of a NEN metastasis excised from the breast of a 72-year-old woman was described by Chodoff [17]. Although recent data suggests that breast secondaries from NENs maybe more frequent than what was thought, based on the idea that many of them have been misdiagnosed in the past as primary NENs or carcinomas [4, 18, 19], they remain a rare phenomenon with no more than 200 cases published in the English literature to date [4, 18–48].

Breast lesions from extramammary primary often pose a diagnostic challenge, since a single breast nodule can be the first and often the only presentation of the disease [48]. In fact, the literature reveals cases of NENs metastatic to the breast with an occult primary carcinoid tumour. However, differentiating between primary and secondary breast lesions is essential, owing to different clinical management and prognosis [41, 48] (Figure 1). The ileum is the most common primary site of metastatic NEN breast lesions, followed by the appendix, duodenum, pancreas, lung and ovary [5, 33, 42, 43]. With regard to cases of bilateral breast metastases from a distant NEN primary, there are about 13 cases reported in the English literature [4, 25, 31, 32, 43, 49–53]. The first case of bilateral breast metastases was from a duodenal carcinoid, published by Hawley [54].




Figure 1. Primary small cell neuroendocrine carcinoma of the breast. (A): Neuroendocrine tumour infiltration from sheets of uniform cells with round nuclei; (B): immunohistochemistry for oestrogen receptor shows nuclear reactivity only in non-neoplastic ductal cells while tumour cells are negative; (C): at least for 50% of the population it shows cytoplasmic reactivity for chromogranin and (D): Very high Ki67 proliferative index.

Method

The cases described in our article were identified and treated at the European Institute of Oncology of Milan, Italy. A literature review was conducted to identify similar cases and characterise features of bilateral or unilateral breast metastases from neuroendocrine tumours.

Results

Case 1: Bilateral breast metastases from a well-differentiated pancreatic neuroendocrine tumour

The first case is that of a 40-year-old woman with a family history of gastric cancer, who presented at our centre after having a pancreaticoduodenectomy for a pancreatic tumour with liver metastases in April 2006. Histology of the primary and biopsy of the liver had shown a well-differentiated endocrine carcinoma (WHO classification 2000), but no other information on Ki67 or other biological features were available. Post-operative somatostatin receptor scintigraphy (SRS) was negative. She was started on somatostatin analogue 30 mg/die (SSA) for 3 months, when the hepatic lesions showed evidence of progression of disease (PD) in October 2006. She was then started on Thalidomide (100 mg/day) and Temozolomide (150 mg/die for 7 days) chemotherapy, followed by loco-regional treatment of liver metastases with trans-arterial embolisation (TAE) and trans-arterial chemoembolisation (TACE) until February 2008. Despite an initial response, she had a slowly but steadily progressive disease on computerised tomography (CT) scan and a rising chromogranin A (CgA) level. In March 2008, a new lesion appeared on the external upper quadrant of the right breast on mammogram. The ultrasound scan confirmed a mass of 10-mm diameter. Cytological examination of the breast nodule initially suggested a breast carcinoma. However, considering the background of the existing metastatic NEN disease, fine needle aspiration (FNA) was repeated but was inconclusive, showing malignant tumour cells (Figure 2). A tru-cut biopsy was carried out which finally confirmed our suspicion of a metastasis from the well-differentiated endocrine carcinoma with a mitotic cell count (Ki67) of 18%, positive for CgA and synaptophysin (SYN), negative for CDX-2, ER/PgR and Her-2 (Figure 3). In July 2008, she was started on capecitabine (2,000 mg/die) and the disease remained stable till May 2009, when the magnetic resonance imaging (MRI) showed an increase of the right breast lesion to 17-mm diameter and the appearance of smaller nodules bilaterally, the largest being 1-cm diameter. The patient was started on Everolimus 10 mg/die, which was stopped after few days due to symptoms of cystitis related to treatment. After this therapy, her general physical condition gradually declined. She developed persistent diarrhoea as sign of disease and became severely dehydrated, leading to a hospital admission. After her hospitalisation, she was started on Octreotide long-acting release (LAR). The patient was last seen in the outpatient clinic in November 2009 with a follow-up CT scan showing extensive disease with multiple metastases in the liver, lungs, breast, bones and lymph nodes. The patient died in December 2009 due to PD.

Case 2: Bilateral breast metastases from an atypical lung carcinoid

The second case we report is that of a 60-year-old female with a previous history of smoking (10 pack-years). She underwent a chest X-ray due to persistent cough, followed by a CT scan of the thorax. A 3.5-cm mass along with multiple smaller satellite nodules (max diameter 1 cm) were seen on the right hemithorax. A fine needle aspiration biopsy (FNAB) resulted in a poorly differentiated carcinoma. In September 2005, she underwent a right pneumonectomy and a lymphadenectomy with histological diagnosis of atypical carcinoid (AC) [55]. The stage was pT4pN1 according to the TNM staging system and the tumour features were CgA and SYN positive, TTF-1 negative, mitotic cell count (Ki67) of 5%, which were confirmed by two pathologists with definitive diagnosis of atypical lung carcinoid. The postoperative CT scans of chest and abdomen were negative. Radiological and clinical follow-up did not show any recurrence of disease until January 2006, when an SRS and a [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan showed high uptake on the breasts. Mammogram confirmed the presence of at least four bilateral breast nodules, the largest was located in the upper external quadrant of the right breast (1.8 cm) and in the lower periareolar area of the left breast (1.5 cm). Histological examination of both the nodules was diagnostic of neuroendocrine tumour, with CgA positive, SYN negative, ER/PgR negative and Ki67 of 15%. In March 2006, the patient underwent a bilateral breast lumpectomy and a sentinel lymph node biopsy. The histological diagnosis was consistent with breast metastases from pulmonary carcinoid grade 2 (WHO 2010) with Ki67 of 15%, CgA, SYN and TTF-1 positive, ER/PgR negative and HER-2 negative. She received adjuvant chemotherapy with six cycles of carboplatin and etoposide with a good response. In November 2006, the patient started developing focal neurological signs with right eyelid ptosis and an MRI of the brain showed metastatic lesions. She received whole brain radiotherapy (3,250 cGy) in September 2007. The disease remained fairly stable up until February 2008 when new bilateral multiple breast lesions appeared on

mammogram, along with brain metastases and pathological mediastinal lymph nodes (LFNs) and lesions on whole body CT scan and FDG-PET scan. In May 2008, peptide receptor radionuclide therapy (PRRT) was started up to December 2008 (with total dosage of 240 mCi of ¹⁷⁷Lu-DOTATE) when a CT scan showed PD in the breast, lung and LFNs. The patient was scheduled for ⁶⁸Ga PET/CT, which she failed to attend, and was lost from follow-up since.




Figure 2. Breast metastases from pancreatic NET (FNA): Cytopathology could not give information about tumour biological features; the neoplastic elements are uniform and consist of small cells with scant cytoplasm, salt-and-pepper chromatin and micronucleoli and consistent neuroendocrine tumour (A and D: HE 40x; B: Papanicolaou 40x; C: Giemsa 100x).




Figure 3. Breast metastases from pancreatic NET (inset: core biopsy). (A): nests of uniform cells with round nuclei; (B): with high proliferative index of 18% by Ki67; (C): immunohistochemistry for chromogranin A shows diffuse cytoplasmic reactivity in tumour cells and (D) on the other hand, only the lobular structures show positivity for CK7.

Case 3: Unilateral breast metastasis from a moderately differentiated lung neuroendocrine tumour

This is the case of a 50-year-old female, with a family history of pancreatic cancer, who was found to have a chest lesion on chest X-ray carried out in 2006 because of intermittent cough since 2000. A subsequent CT scan of the thorax confirmed a 13-mm nodule on the upper right lobe of the lung, which did not seem suspicious for malignancy. Following a FDG-PET, which did not pick up on the nodule (SUV max 1.25), observation of the lesion was decided with yearly scans. Up until 5 years later, the lesion seemed to have remained unchanged. However, the imaging follow-up of December 2010 showed a new lesion in the right breast. In January 2011, she underwent right breast quadrantectomy for a lump histologically perceived as an infiltrating triple negative lobular carcinoma, with a negative sentinel node. This result was confirmed from a second pathologist later on. Surgery was followed by adjuvant chemotherapy and radiotherapy, completed in July 2011. In August 2012, a left breast nodule was detected on mammogram and confirmed on MRI. Biopsy of the lesion resulted in a triple negative invasive ductal carcinoma. A PET/CT with FDG was carried out which surprisingly showed a high uptake only on the old pulmonary nodule, which had increased in the meantime, becoming 3 cm in diameter (SUV max 5.9). Biopsy of the lesion was suspicious for a carcinoid. In June 2012, the patient underwent a right lobectomy and right hilomediastinic lymph node dissection. Histology reported a neuroendocrine neoplasm with Ki67 of 18%. Clinically, the patient showed PD from the left breast with subcutaneous nodules formation. It was decided to proceed to a bilateral mastectomy with subcutaneous nodules removal in July 2012. The histological result showed a neuroendocrine tumour, Ki67 of 12% and negative left sentinel node. A second pathology opinion was concluded for breast metastases and subcutaneous nodules from a moderately differentiated NEN of pulmonary origin, with Ki67 of 14% positive for CgA and TTF-1 and negative for calcitonin and somatostatin receptors (SSTR2), concluding for an AC (Figure 4). A follow-up 68Ga-PET/DOTATOC, CT with contrast medium and MRI showed further lesions on left and right femur. Biopsy of the left femoral lesion confirmed a metastasis from the same moderately differentiated NEN with Ki67 of 16% with negative somatostatin receptor (SSTR). In view of disease progression, it was decided to start chemotherapy in January 2013 with capecitabine (1,500 mg/m²/die for 14 days) and temozolomide (150 mg/m² for 5 days). The patient tolerated well the first six cycles which were stopped due to thrombopenia (grade 3) and malaise and were switched to subcutaneous (SC) octreotide LAR 30 mg/die. A follow-up CT scan showed a new pulmonary nodule of 3 mm on the left and an ultrasound of the thyroid revealed nodule on the right lobe of 15 × 12 mm, which was aspirated and confirmed the metastatic nature of the primary pulmonary lesion. The patient was reluctant to undergo for further chemotherapy at that time, and thus decided to continue with the somatostatin analogue and re-evaluate the situation in few months. In August 2013, her disease was clinically and radiologically stable.




Figure 4. Metastatic breast NET from lung carcinoid. (A): Breast tissue infiltrated in lobular carcinoma fashion; (B): immunohistochemistry for CK7 and for synaptophysin; (C): diffuse cytoplasmic reactivity in tumour cells and (D) with typical pagetoid involvement of the hyperplastic duct.

Case 4: Unilateral breast metastasis from an atypical lung carcinoid

This is the case of a 68-year-old woman with a past medical history of a right radical mastectomy for a primary breast carcinoma at the age of 40. In 2004, she was admitted to the hospital for a suspected pulmonary embolism. The CT scan of the thorax revealed a 2-cm mass occluding the left bronchus. In October 2004, she underwent left inferior lobectomy and was histologically diagnosed as having an atypical pulmonary carcinoid. The follow-up was negative until October 2007, when a nodule in the right lobe of the thyroid was detected. FNAB revealed a suspected papillary neoplasm and she underwent total thyroidectomy in January 2008. The histological analysis indicated a metastasis from the lung NEN. Three months post-thyroidectomy, CT of chest/abdomen, SRS and 68Ga PET scans were all negative. However, FDG-PET revealed a 7-mm nodule in the left breast; thus, she underwent quadrantectomy in September 2008. The histological diagnosis was a NEN metastasis that was positive for CgA, SYN and CD56, and negative for ER, PGR, HER-2 and negative for SSTR 2, 3 and 5. In January 2009, she was restaged with a chest X-ray, thyroid ultrasound and bone scan, Blood CgA and neuron-specific enolase (NSE), as well as imaging was negative for PD.

Discussion

NENs are a heterogeneous group of uncommon malignancies originating from the diffuse endocrine system. While poorly differentiated NENs have an aggressive behaviour with a poor prognosis, well-differentiated NENs are usually slowly progressing even though they can give metastatic spread to distant sites, mainly to the liver. In 2010, the WHO published the new classification of gastroenteropancreatic (GEP) NENs based on proliferation index (Ki-67) and/or mitotic index (MI), aiming to differentiate between tumours [neuroendocrinal tumors (NETs)] and carcinomas [neuroendocrinal carcinomas (NECs)]. In particular, NETs include grade 1 (Ki67 < 2% and/or MI ≤ 2/10 high power field, HPF) and grade 2 (3% < Ki67 < 20% and/or 3 < MI < 20/HPF) NENs, whereas NECs refer to the grade 3 (Ki67 > 20% and/or MI > 20/HPF) [56]. This grading is a strong predictor of prognosis. In fact, in the well to moderately differentiated NETs, survival at 5 years reaches 35%, whereas in the poorly differentiated NECs it is less than 5% [57]. On the other hand, according to the 2004 WHO classification, four major types of lung neuroendocrine neoplasms are recognised: typical carcinoid, AC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma [55].

NENs can develop in any part of the body, most commonly in the gastrointestinal tract. The ileum was found to be the most common primary site of metastatic breast NENs. The appendix, duodenum, pancreas, lungs and ovaries were the other primary sites from where NENs metastasise to the breast [5, 33, 36, 42, 43]. Breast metastases from NENs are not common, although there is an increased frequency reported over the last years. This could be the result of more NEN breast metastases being correctly diagnosed, as specialists are more conscious that these lesions can resemble primary carcinomas and modern technology imaging aids in reaching the correct diagnosis [5, 18, 19, 51]. In particular, an increased occurrence of breast metastases from GEP NENs has been reported [58]. One of the first cases of metastatic NEN to the breast was published in 1977. This was the case of a 58-year-old woman who presented with an isolated breast mass, which was subsequently found to be the metastasis from a bronchial carcinoid [27, 59]. In fact, a solitary breast lump may often be the first and only manifestation of the disease and can mimic a primary breast carcinoma [25, 48, 51]. The mean age of presentation for metastatic breast NENs is considered to be 56 years, which is by 10 years younger than the patients presenting with primary NENs of the breast, usually in their sixth and seventh decade of life [22]. However, the presentation of bilateral NEN metastases to the breast remains an extremely rare manifestation of the disease [1, 31, 32, 60].

Breast metastases from NEN represent an important diagnostic challenge for practitioners because of the difficulty to differentiate from a primary breast carcinoma. An accurate study of the tumour characteristics and patient clinical history are necessary in order to decide on adequate medical and surgical treatment [32, 36, 41, 43, 48]. Histology and immunohistochemistry can be useful in the recognition of the neuroendocrine structure of the tumour. Neuroendocrine tumours typically form nests or sheets of uniform cell populations with abundant eosinophilic cytoplasm and round nuclei. At least 50% of the cell population must be immunoreactive for at least one neuroendocrine marker, including SYN, CgA and B, NSE and negative for cytokeratin 7, whereas breast carcinoma strongly express cytokeratin 7. The SSTR expression is usually negative in breast carcinoma unlike NENs (even though in some cases NENs may lack expression of SSTR expression). Oestrogen and progesterone hormone receptors do not help to differentiate breast carcinoma from primary breast NEN, as may be positive in both cases, whereas metastatic NENs are typically negative for hormone receptors and Her-2 [1, 20, 29, 34, 61]. In fact, immunohistochemical

determinations in all the cases we reported showed a positive staining for chromogranin A and synaptophysin, while ER, PgR and HER-2 were not expressed, confirming the neuroendocrine nature of the lesions. In two of the above-mentioned cases, SSTR immunohistochemical determination was carried out and the absence of somatostatin receptors could explain why the SRS and 68Ga PET did not pick up any abnormality. Nevertheless, FNA is considered to be the best diagnostic procedure for a correct diagnosis of breast nodules [30, 32, 62, 63]. It is worth mentioning that this needs to be carried out with caution, as it can precipitate a carcinoid crisis in the case of hormonally active tumours [20]. In addition, it has been shown that histological analysis and morphological evaluation with the use of auxiliary immunohistochemical studies are important in reaching a correct diagnosis, particularly in difficult cases such as those with an unknown primary [32, 36]. Morphological distinction is often difficult on both FNA and lumpectomy specimens due to several overlapping features and the reported frequency of neuroendocrine cells (~25%) in breast carcinoma [13, 64–68].

Moreover, morphological and functional imaging can play an important role in differential diagnosis. At mammographic evaluation, the breast NET appears as a more round circumscribed mass, while the breast carcinoma has more speculated edges and often has evidence of microcalcifications, which are usually absent in a NEN of the breast [67, 69].

On the other hand, radiological imaging cannot offer much in differentiating the various lesions. The appearance of breast nodules on MRI and ultrasound is substantially similar to the case of metastatic and primary NENs, as well as the case of breast carcinoma [22, 26, 69]. Additional radionuclide imaging can be useful in differentiating NENs, as the majority of them express SSTR compared to ductal mammary carcinomas [25, 28, 70]. A recent study showed that 68Ga PET/CT-DOTATOC in patients with NEN enables detection of cardiac and breast metastases from NENs, as well as other rare sites [19]. However, imaging characteristics alone are not sufficient for a definitive diagnosis. Fine needle aspiration or core needle biopsy is necessary to confirm or exclude suspicion. Finally, also an in-depth medical history may play an important role in differentiating a primary from a breast metastasis. Previous history of NENs, even if radically treated or with low-grade features, needs to be considered as a potential primary of future metastases. To a lesser extent, synchronous or subsequent second primary malignancies related to NEN have also been reported [46].

There are no clear recommendations about the surgical approach of these tumours. It is suggested that a localised primary breast NEN should be treated as an invasive ductal carcinoma with mastectomy or breast conserving therapy with lumpectomy and negative margins, as well as axillary staging with sentinel lymph node biopsy [1, 71–73]. However, confirming negative surgical margins can be challenging, as neuroendocrine carcinomas may have pagetoid involvement or a background of hyperplasia can produce artefacts [74, 75]. With regard to patients with breast metastases from NEN, a lumpectomy alone is recommended, whereas mastectomy is advisable only if there are numerous large metastatic NENs to the breast. Multiple resections would be recommended in the presence of more than one lesion, aiming to locally control the disease and preserve the breast [41, 76]. Debulking of metastases often offer better survival compared to no resection [77]. If palpable adenopathy is absent, axillary lymph node dissection is not deemed necessary [41]. Accurate recognition of the entity is vital to avoid unnecessary treatment [25].

In addition to surgical treatments, the need for medical therapy either locally or more frequently systemic arises, depending on the site and extension of metastases, clinical history and symptoms. In case of unresectable and symptomatic NEN hepatic metastases, transarterial liver-directed therapies, such as radiofrequency thermal ablation, TAE, TACE or selective internal radiation therapy could be an option for symptomatic relief and reduction of hormone levels [78]. Systemic treatments may consist of fluoropyrimidine, oxaliplatin or temozolomide-based chemotherapy, depending on previous treatments and the primary tumour site. If SSTR expression on SRS or 68Ga PET scan is present, PRRT treatment may be indicated to control tumour growth, combined with SSAs for symptoms control, especially in case of carcinoid syndrome [79, 80].

We report the cases of four female patients who developed breast lumps, two bilateral and two unilateral, mimicking the clinical and histological features of breast carcinomas on a background of previous NENs; two atypical lung carcinoids, a well-differentiated pancreatic NET and a moderately differentiated NET from pulmonary origin. We observed that in the majority of the reported cases, patients were initially misdiagnosed, mainly as having mammary carcinomas, resulting in inappropriate breast surgery and axillary dissection instead of systemic specific treatment. Only later the histological review of surgical specimens led to the correct diagnosis, as it happened in our last case. However, suspicion may not always be raised, particularly in the cases where the primary tumour was never found [4, 71]. Patients presenting with breast nodules and having a past history of NENs or typical symptoms of carcinoid syndrome (flushing, watery diarrhoea, abdominal pain and tachycardia) must always be considered as having a potentially metastatic disease, even in the case of a previous well-differentiated NET. Since it is not always possible to detect a primary extramammary NET, a single breast lesion can be easily thought as the primary NET.

Nonetheless, this term is subject to controversies and it is thought that a 'mammary carcinoma with endocrine features' is more adequate [19, 26, 28, 62, 63]. Clinically, there are no criteria to distinguish metastatic breast NET from primary breast endocrine tumours [69]. *In situ* ductal carcinoma with neuroendocrine expression may be the only proof of the primary nature of the breast lesion. Although a challenge, meticulous investigations and medical history are crucial in order to reach the correct diagnosis and differentiate between primary and secondary breast tumours.

Conclusion

Breast metastases from NETs are not seen often in clinical practice; nevertheless, practitioners need to be alert and investigate in detail a patient presenting with a breast mass in order to rule out metastasis. Bilateral breast metastases originating from NETs are exceptionally rare. However, it is important to differentiate between a primary and secondary breast lesions, as this will define management and prognosis. Clinical and histological similarities make diagnosis particularly difficult at times, especially when there is an absence of a known primary. In addition, clear guidelines regarding management are lacking and yet more experience is needed to determine the best approach. A practitioner should consider all aspects when deciding a treatment option. Tumour features, patient's clinical status and perspectives, as well as short and long-term objectives will all need to be taken into account in order to choose the best therapeutic strategy.

Conflicts of interest

The authors have nothing to disclose.

Funding

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Acknowledgment

The authors would like to thank their patients and their families.

References

1. Amin AL and Kong AL (2011) **Metastatic neuroendocrine tumor found on screening mammogram** *WMJ* 110(3) 140–143; quiz 5 PMID: [21749000](https://pubmed.ncbi.nlm.nih.gov/21749000/)
2. Narese D, Virzi V, and Narese F, *et al* (2014) **Breast core biopsy of a rare case of unknown primary large cell neuroendocrine carcinoma metastatic to the breast** *Clin Ter* 165(6) 302–304 PMID: [25524186](https://pubmed.ncbi.nlm.nih.gov/25524186/)
3. DeLair DF, Corben AD, and Catalano JP, *et al* (2012) **Non-mammary metastases to the breast and axilla: a study of 85 cases** *Mod Pathol* 26(3) 343–349 <https://doi.org/10.1038/modpathol.2012.191> PMID: [23174933](https://pubmed.ncbi.nlm.nih.gov/23174933/)
4. Perry KD, Reynolds C, and Rosen DG, *et al* (2011) **Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma** *Histopathology* 59(4) 619–630 <https://doi.org/10.1111/j.1365-2559.2011.03940.x> PMID: [22014043](https://pubmed.ncbi.nlm.nih.gov/22014043/)
5. Georgiannos SN, Chin J, and Goode AW, *et al* (2001) **Secondary neoplasms of the breast: a survey of the 20th century** *Cancer* 92(9) 2259–2266 [https://doi.org/10.1002/1097-0142\(20011101\)92:9<2259::AID-CNCR1571>3.0.CO;2-O](https://doi.org/10.1002/1097-0142(20011101)92:9<2259::AID-CNCR1571>3.0.CO;2-O) PMID: [11745279](https://pubmed.ncbi.nlm.nih.gov/11745279/)
6. Lee SK, Kim WW, and Kim SH, *et al* (2010) **Characteristics of metastasis in the breast from extramammary malignancies** *J Surg Oncol* 101(2) 137–140 <https://doi.org/10.1002/jso.21453> PMID: [20082359](https://pubmed.ncbi.nlm.nih.gov/20082359/)

7. Baba M, Higaki N, and Ishida M, *et al* (2002) **A male patient with metachronous triple cancers of small cell lung, prostate and breast** *Breast Cancer* 9(2) 170–174 <https://doi.org/10.1007/BF02967583> PMID: [12016398](https://pubmed.ncbi.nlm.nih.gov/12016398/)
8. Genc B, Solak A, and Sahin N, *et al* (2013) **Metastasis to the male breast from squamous cell lung carcinoma** *Case Rep Oncol Med* 2013 593970 PMID: [23997970](https://pubmed.ncbi.nlm.nih.gov/23997970/) PMCID: [3755418](https://pubmed.ncbi.nlm.nih.gov/3755418/)
9. Schmitt FC and Brandao M (1990) **Carcinoid tumour of male breast diagnosed by fine needle aspiration** *Cytopathology* 1(4) 251–255 <https://doi.org/10.1111/j.1365-2303.1990.tb00355.x> PMID: [1714307](https://pubmed.ncbi.nlm.nih.gov/1714307/)
10. Lingappa HA, Indushekar V, and Chamarthy NP, *et al* (2014) **Primary neuroendocrine carcinoma of male breast: a cytologically diagnosed rare entity** *J Cytol/Indian Acad Cytol* 31(2) 105–107 <https://doi.org/10.4103/0970-9371.138685>
11. Makhdoomi R, Mustafa F, and Ahmad R, *et al* (2013) **Bilateral breast metastasis from mucinous adenocarcinoma of the rectum: a case report and review of the literature** *Turk Patoloji Derg* 29(3) 231–234 PMID: [24022315](https://pubmed.ncbi.nlm.nih.gov/24022315/)
12. Ang D, Ballard M, and Beadling C, *et al* (2015) **Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets** *Appl Immunohistochem Mol Morphol* 23(2) 97–103 <https://doi.org/10.1097/PDM.Ob013e3182a40fd1> PMID: [25679062](https://pubmed.ncbi.nlm.nih.gov/25679062/)
13. Brask JB, Talman ML, and Wielenga VT (2014) **Neuroendocrine carcinoma of the breast—a pilot study of a Danish population of 240 breast cancer patients** *APMIS* 122(7) 585–592 <https://doi.org/10.1111/apm.12197>
14. Rovera F, Lavazza M, and La Rosa S, *et al* (2013) **Neuroendocrine carcinoma of the breast—a pilot study of a Danish population of 240 breast cancer patients** *Int J Surg* 11(Suppl 1) S79–S83 [https://doi.org/10.1016/S1743-9191\(13\)60023-0](https://doi.org/10.1016/S1743-9191(13)60023-0)
15. Sherwell-Cabello S, Maffuz-Aziz A, and Hernandez-Hernandez B, *et al* (2015) **Primary neuroendocrine tumor of the breast** *Breast J* 21(3) 312–313 <https://doi.org/10.1111/tbj.12413> PMID: [25808825](https://pubmed.ncbi.nlm.nih.gov/25808825/)
16. Valentim MH, Monteiro V, and Marques JC (2014) **Primary neuroendocrine breast carcinoma: a case report and literature review** *Radiol Bras* 47(2) 125–127 <https://doi.org/10.1590/S0100-39842014000200017>
17. Chodoff RJ (1965) **Solitary Breast Metastasis from Carcinoid of the Ileum** *Am J Surg* 109 814–815 [https://doi.org/10.1016/S0002-9610\(65\)80059-9](https://doi.org/10.1016/S0002-9610(65)80059-9) PMID: [14283346](https://pubmed.ncbi.nlm.nih.gov/14283346/)
18. Crona J, Granberg D, and Norlen O, *et al* (2013) **Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall?** *World J Surg* 37(7) 1701–1706 <https://doi.org/10.1007/s00268-013-2037-2> PMID: [23592057](https://pubmed.ncbi.nlm.nih.gov/23592057/)
19. Carreras C, Kulkarni HR, and Baum RP (2012) **Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors** *Recent Results Cancer Res* 194 379–384 https://doi.org/10.1007/978-3-642-27994-2_20 PMID: [22918770](https://pubmed.ncbi.nlm.nih.gov/22918770/)
20. Adams RF, Parulekar V, and Hughes C, *et al* (2009) **Radiologic characteristics and management of screen-detected metastatic carcinoid tumor of the breast: a case report** *Clin Breast Cancer* 9(3) 189–192 <https://doi.org/10.3816/CBC.2009.n.032> PMID: [19661045](https://pubmed.ncbi.nlm.nih.gov/19661045/)
21. Ahlman H, Larsson I, and Gronstad K, *et al* (1986) **A case of midgut carcinoid with breast metastasis and cellular localization of serotonin and substance P** *J Surg Oncol* 31(3) 170–173 <https://doi.org/10.1002/jso.2930310306> PMID: [2425188](https://pubmed.ncbi.nlm.nih.gov/2425188/)
22. Amin AL and Kong AL (2011) **Metastatic neuroendocrine tumor found on screening mammogram** *WMJ* 110(3) 140–143 quiz 5 PMID: [21749000](https://pubmed.ncbi.nlm.nih.gov/21749000/)
23. Choi JJ, Buch KE, and Warner RR, *et al* (2011) **Atypical lung carcinoid metastasis to breast: a case report** *Pancreas* 40(3) 487–488 <https://doi.org/10.1097/MPA.Ob013e31820b4e19> PMID: [21412125](https://pubmed.ncbi.nlm.nih.gov/21412125/)
24. Fishman A, Kim HS, and Girtanner RE, *et al* (1994) **Solitary breast metastasis as first manifestation of ovarian carcinoid tumor** *Gynecol Oncol* 54(2) 222–226 <https://doi.org/10.1006/gyno.1994.1198> PMID: [8063251](https://pubmed.ncbi.nlm.nih.gov/8063251/)
25. Glazebrook KN, Jones KN, and Dilaveri CA, *et al* (2011) **Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall?** *Cancer Imaging* 11 109–115 <https://doi.org/10.1102/1470-7330.2011.0018> PMID: [21771708](https://pubmed.ncbi.nlm.nih.gov/21771708/) PMCID: [3205760](https://pubmed.ncbi.nlm.nih.gov/3205760/)

26. Gupta C, Malani AK, and Rangineni S (2006) **Breast metastasis of ilial carcinoid tumor: case report and literature review** *World J Surg Oncol* 4 15 <https://doi.org/10.1186/1477-7819-4-15> PMID: 16566835 PMCID: 1481627
27. Harrist TJ and Kalisher L (1977) **Breast metastasis: an unusual manifestation of a malignant carcinoid tumor** *Cancer* 40(6) 3102–3106 [https://doi.org/10.1002/1097-0142\(197712\)40:6<3102::AID-CNCR2820400652>3.0.CO;2-N](https://doi.org/10.1002/1097-0142(197712)40:6<3102::AID-CNCR2820400652>3.0.CO;2-N) PMID: 338142
28. Kaltsas GA, Putignano P, and Mukherjee JJ, et al (1998) **Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetretotide** *Clin Endocrinol (Oxf)* 49(5) 685–689 <https://doi.org/10.1046/j.1365-2265.1998.00527.x>
29. Kanthan R, Negreiros F, and Kanthan SC (2003) **Colonic carcinoid metastatic to the breast** *Arch Pathol Lab Med* 127(10) 1373–1375 PMID: 14521451
30. Landon G, Sneige N, and Ordonez NG, et al (1987) **Carcinoid metastatic to breast diagnosed by fine-needle aspiration biopsy** *Diagn Cytopathol* 3(3) 230–233 <https://doi.org/10.1002/dc.2840030311> PMID: 3665690
31. Lozowski MS, Faegenburg D, and Mishriki Y, et al (1989) **Carcinoid tumor metastatic to breast diagnosed by fine needle aspiration. Case report and literature review** *Acta Cytol* 33(2) 191–194 PMID: 2929220
32. Mosunjac MB, Kochhar R, and Mosunjac MI, et al (2004) **Primary small bowel carcinoid tumor with bilateral breast metastases: report of 2 cases with different clinical presentations** *Arch Pathol Lab Med* 128(3) 292–297 PMID: 14987160
33. Nielsen M, Andersen JA, and Henriksen FW, et al (1981) **Metastases to the breast from extramammary carcinomas** *Acta Pathol Microbiol Scand A* 89(4) 251–256 PMID: 7315321
34. Ogawa H, Nishio A, and Satake H, et al (2008) **Neuroendocrine tumor in the breast** *Radiat Med* 26(1) 28–32 <https://doi.org/10.1007/s11604-007-0182-y> PMID: 18236131
35. Ordonez NG, Manning JT, Jr., and Raymond AK (1985) **Argentaffin endocrine carcinoma (carcinoid) of the pancreas with concomitant breast metastasis: an immunohistochemical and electron microscopic study** *Hum Pathol* 16(7) 746–751 [https://doi.org/10.1016/S0046-8177\(85\)80164-7](https://doi.org/10.1016/S0046-8177(85)80164-7) PMID: 3891579
36. Rubio IT, Korourian S, and Brown H, et al (1998) **Carcinoid tumor metastatic to the breast** *Arch Surg* 133(10) 1117–1119 <https://doi.org/10.1001/archsurg.133.10.1117> PMID: 9790211
37. Satahoo-Dawes S, Palmer J, and Iii EW, et al (2011) **Breast and lung metastasis from pancreatic neuroendocrine carcinoma** *World J Radiol* 3(1) 32–37 <https://doi.org/10.4329/wjr.v3.i1.32> PMID: 21286493 PMCID: 3030725
38. Schurch W, Lamoureux E, and Lefebvre R, et al (1980) **Solitary breast metastasis: first manifestation of an occult carcinoid of the ileum** *Virchows Arch A Pathol Anat Histol* 386(1) 117–124 <https://doi.org/10.1007/BF00432649> PMID: 7405004
39. Shahrokni A, Rajebi MR, and Saif MW (2009) **Breast metastasis of small bowel carcinoid tumor misdiagnosed as primary breast cancer** *Ann Saudi Med* 29(4) 320–321 <https://doi.org/10.4103/0256-4947.55317> PMID: 19584577 PMCID: 2841464
40. Shetty MR and Ahmed MI (1995) **12 cases of carcinoid tumors metastatic to the breast have been reported** *Gynecol Oncol* 57(3) 436–437 PMID: 7774854
41. Upalakalin JN, Collins LC, and Tawa N, et al (2005) **Carcinoid tumors in the breast** *Am J Surg* 191(6) 799–805 <https://doi.org/10.1016/j.amjsurg.2005.10.021>
42. Vergier B, Trojani M, and de Mascarel I, et al (1991) **Metastases to the breast: differential diagnosis from primary breast carcinoma** *J Surg Oncol* 48(2) 112–116 <https://doi.org/10.1002/jso.2930480208> PMID: 1921396
43. Williams SA, Ehlers RA, and Hunt KK, et al (2007) **Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival** *Cancer* 110(4) 731–737 <https://doi.org/10.1002/cncr.22835>

44. Wozniak TC and Naunheim KS (1998) **Bronchial carcinoid tumor metastatic to the breast** *Ann Thorac Surg* 65(4) 1148–1149 [https://doi.org/10.1016/S0003-4975\(98\)00052-6](https://doi.org/10.1016/S0003-4975(98)00052-6) PMID: 9564951
45. Carreras C, Kulkarni HR, and Baum RP (2013) **Rare metastases detected by (68)Ga-somatostatin receptor PET/CT in patients with neuroendocrine tumors** *Recent Results Cancer Res* 194 379–384 https://doi.org/10.1007/978-3-642-27994-2_20
46. Clift AK, Drymoussis P, and Al-Nahhas A, et al (2015) **Incidence of second primary malignancies in patients with neuroendocrine tumours** *Neuroendocrinology* 102(1–2) 26–32 <https://doi.org/10.1159/000381716> PMID: 25824138
47. Gaur S, Ayyappan AP, and Nahleh Z (2013) **Breast metastases from an adrenocorticotrophic hormone secreting thymic neuro-endocrine tumor** *Breast Dis* 34(2) 81–86 <https://doi.org/10.3233/BD-130354> PMID: 23948804
48. La Rosa S, Casnedi S, and Maragliano R, et al (2015) **Breast metastasis as the first clinical manifestation of ileal neuroendocrine tumor. A challenging diagnosis with relevant clinical implications** *Endocr Pathol* 26(2) 145–151 <https://doi.org/10.1007/s12022-015-9371-x> PMID: 25935445
49. Ballesio L, Di Pastena F, and Ravazzolo N, et al (2012) **Neuroendocrine lung cancer presenting as a breast lump** *Clin Ter* 163(3) 219–221 PMID: 22964695
50. Hwang H, Hou KT, and Schiller CL, et al (2008) **Neuroendocrine carcinoma metastatic to the breast** *Breast J* 14(2) 201–202 <https://doi.org/10.1111/j.1524-4741.2007.00557.x> PMID: 18248556
51. Perry KD, Reynolds C, and Rosen DG, et al (2011) **Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma** *Histopathology* 59(4) 619–630 <https://doi.org/10.1111/j.1365-2559.2011.03940.x> PMID: 22014043
52. Wee A, Nilsson B, and Chong SM, et al (1992) **Bilateral carcinoid tumor of the breast. Report of a case with diagnosis by fine needle aspiration cytology** *Acta Cytol* 36(1) 55–59 PMID: 1546512
53. Basu S and Abhyankar A (2014) **The use of 99mTc-HYNIC-TOC and 18F-FDG PET/CT in the evaluation of duodenal neuroendocrine tumor with atypical and extensive metastasis responding dramatically to a single fraction of PRRT with 177Lu-DOTATATE** *J Nucl Med Technol* 42(4) 296–298 <https://doi.org/10.2967/jnmt.114.139238> PMID: 25190735
54. Hawley PR (1966) **A case of secondary carcinoid tumours in both breasts following excision of primary carcinoid tumour of the duodenum** *Br J Surg* 53(9) 818–820 <https://doi.org/10.1002/bjs.1800530922> PMID: 5911773
55. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (2004) *Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart* (Lyon, France: IARC Press) 2004
56. Oberg K and Castellano D (2011) **Current knowledge on diagnosis and staging of neuroendocrine tumors** *Cancer Metastasis Rev* 30(Suppl 1) 3–7 <https://doi.org/10.1007/s10555-011-9292-1> PMID: 21311954
57. Pavel M, Baudin E, and Couvelard A, et al (2012) **ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary** *Neuroendocrinology* 5(2) 157–176 <https://doi.org/10.1159/000335597>
58. Kamp K, Damhuis RA, and Feelders RA, et al (2012) **Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas** *Endocr Relat Cancer* 19(1) 95–99 <https://doi.org/10.1530/ERC-11-0315>
59. Cubilla AL and Woodruff JM (1977) **Primary carcinoid tumor of the breast: a report of eight patients** *Am Surg Pathol* 1 283 <https://doi.org/10.1097/00000478-197712000-00001>
60. Zhang JY and Chen WJ (2011) **Bilateral primary breast neuroendocrine carcinoma in a young woman: report of a case** *Surg Today* 41(11) 1575–1578 <https://doi.org/10.1007/s00595-010-4516-5> PMID: 21969166

61. Wei B, Ding T, and Xing Y, *et al* (2010) **Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma** *Cancer* **116**(19) 4463–4473 <https://doi.org/10.1002/cncr.25352> PMID: [20572042](https://pubmed.ncbi.nlm.nih.gov/20572042/)
62. Hartgrink HH, Lagaay MB, and Spaander PJ, *et al* (1995) **A series of carcinoid tumours of the breast** *Eur J Surg Oncol* **21**(6) 609–612 [https://doi.org/10.1016/S0748-7983\(95\)95219-5](https://doi.org/10.1016/S0748-7983(95)95219-5) PMID: [8631405](https://pubmed.ncbi.nlm.nih.gov/8631405/)
63. Kvols LK and Buck M (1987) **Chemotherapy of metastatic carcinoid and islet cell tumors. A review** *Am J Med* **82**(5B) 77–83 [https://doi.org/10.1016/0002-9343\(87\)90430-X](https://doi.org/10.1016/0002-9343(87)90430-X) PMID: [3035924](https://pubmed.ncbi.nlm.nih.gov/3035924/)
64. Cloyd JM, Yang RL, and Allison KH, *et al* (2014) **Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast** *Breast Cancer Res Treat* **148**(3) 637–644 <https://doi.org/10.1007/s10549-014-3207-0> PMID: [25399232](https://pubmed.ncbi.nlm.nih.gov/25399232/)
65. Crona J, Granberg D, and Norlen O, *et al* (2013) **Metastases from neuroendocrine tumors to the breast are more common than previously thought. A diagnostic pitfall?** *World J Surg* **37**(7) 1701–1706 <https://doi.org/10.1007/s00268-013-2037-2> PMID: [23592057](https://pubmed.ncbi.nlm.nih.gov/23592057/)
66. Nandeesh M, Anitha TK, and Rajpurohit S, *et al* (2013) **Neuroendocrine carcinoma of breast: a rare case vignette** *JCDR* **7**(11) 2585–2586
67. Park YM, Wu Y, and Wei W, *et al* (2014) **Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features** *AJR Am J Roentgenol* **203**(2) W221–W230 <https://doi.org/10.2214/AJR.13.10749> PMID: [25055297](https://pubmed.ncbi.nlm.nih.gov/25055297/)
68. Wachter DL, Hartmann A, and Beckmann MW, *et al* (2014) **Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma** *BioMed Res Int* **2014** 408459 <https://doi.org/10.1155/2014/408459> PMID: [24701575](https://pubmed.ncbi.nlm.nih.gov/24701575/) PMCID: [3950407](https://pubmed.ncbi.nlm.nih.gov/3950407/)
69. Jeon CH, Kim SM, and Jang M, *et al* (2014) **Clinical and radiologic features of neuroendocrine breast carcinomas** *J Ultrasound Med* **33**(8) 1511–1518 <https://doi.org/10.7863/ultra.33.8.1511> PMID: [25063418](https://pubmed.ncbi.nlm.nih.gov/25063418/)
70. Alberini JL, Meunier B, and Denzler B, *et al* (2000) **Somatostatin receptor in breast cancer and axillary nodes: study with scintigraphy, histopathology and receptor autoradiography** *Breast Cancer Res Treat* **61**(1) 21–32 <https://doi.org/10.1023/A:1006447325077> PMID: [10930087](https://pubmed.ncbi.nlm.nih.gov/10930087/)
71. Angarita FA, Rodriguez JL, and Meek E, *et al* (2013) **Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature** *World J Surg Oncol* **11** 128 <https://doi.org/10.1186/1477-7819-11-128> PMID: [23734899](https://pubmed.ncbi.nlm.nih.gov/23734899/) PMCID: [3682896](https://pubmed.ncbi.nlm.nih.gov/3682896/)
72. Van Laarhoven HA, Gratama S, and Wereldsma JC (1991) **Neuroendocrine carcinoid tumours of the breast: a variant of carcinoma with neuroendocrine differentiation** *J Surg Oncol* **46**(2) 125–132 <https://doi.org/10.1002/jso.2930460211> PMID: [1704078](https://pubmed.ncbi.nlm.nih.gov/1704078/)
73. Lu CS, Huang SH, and Ho CL, *et al* (2014) **Primary neuroendocrine carcinoma of the breast** *J BUON* **19**(2) 419–429 PMID: [24965401](https://pubmed.ncbi.nlm.nih.gov/24965401/)
74. Kawasaki T, Nakamura S, and Sakamoto G, *et al* (2008) **Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast--comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases** *Histopathology* **53**(3) 288–298 <https://doi.org/10.1111/j.1365-2559.2008.03093.x> PMID: [18657193](https://pubmed.ncbi.nlm.nih.gov/18657193/)
75. Miura K, Nasu H, and Ogura H (2012) **Double neuroendocrine ductal carcinomas in situ coexisting with a background of diffuse idiopathic neuroendocrine cell hyperplasia of breast: a case report and hypothesis of neuroendocrine tumor development** *Pathol Int* **62**(5) 331–334 <https://doi.org/10.1111/j.1440-1827.2012.02786.x> PMID: [22524661](https://pubmed.ncbi.nlm.nih.gov/22524661/)
76. Berruti A, Saini A, and Leonardo E, *et al* (2004) **Management of neuroendocrine differentiated breast carcinoma** *Breast* **13**(6) 527–529 <https://doi.org/10.1016/j.breast.2004.06.007> PMID: [15563864](https://pubmed.ncbi.nlm.nih.gov/15563864/)
77. Abood GJ, Go A, and Malhotra D, *et al* (2009) **The surgical and systemic management of neuroendocrine tumors of the pancreas** *Surg Clin North Am* **89**(1) 249–266 <https://doi.org/10.1016/j.suc.2008.10.001> PMID: [19186239](https://pubmed.ncbi.nlm.nih.gov/19186239/)
78. Nazario J and Gupta S (2010) **Transarterial liver-directed therapies of neuroendocrine hepatic metastases** *Semin Oncol* **37**(2) 118–126 <https://doi.org/10.1053/j.seminoncol.2010.03.004> PMID: [20494704](https://pubmed.ncbi.nlm.nih.gov/20494704/)

79. Kjaer A and Knigge U (2015) **Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors** *Scand J Gastroenterol* **50**(6) 740–747 <https://doi.org/10.3109/00365521.2015.1033454> PMID: [25959100](https://pubmed.ncbi.nlm.nih.gov/25959100/) PMCID: [4487540](https://pubmed.ncbi.nlm.nih.gov/4487540/)
80. Rai U, Thrimawithana TR, and Valery C, *et al* (2015) Therapeutic uses of somatostatin and its analogues: Current view and potential applications. *Pharmacol Ther* **152** 98–110